Liquid Biopsies to Distinguish Malignant from Benign Pulmonary Nodules

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2021 May 7

PMID 33960710

Citations 15

Authors

Rui Tao

Wei Cao

Feng Zhu

Jinfu Nie

Hongzhi Wang

Lixiang Wang

Pengcheng Liu

Hailong Chen

Bo Hong

Dahai Zhao

Affiliations

Soon will be listed here.

Abstract

Over the past decades, low-dose computed tomography (LD-CT) screening has been widely used for the early detection of lung cancer. Increasing numbers of indeterminate pulmonary nodules are now being discovered. However, it remains challenging to distinguish malignant from benign pulmonary nodules, especially those considered to be small or ground-glass (GGN) nodules. Liquid biopsies have been successfully applied in the diagnosis of advanced lung cancer, and the potential value for early detection of lung cancer has made great progress. Recent studies have demonstrated the value of various blood-based tumor biomarkers in determining the nature of pulmonary nodules, including cell-free DNA (cfDNA), microRNAs (miRNAs), circulating tumor cells (CTCs) and tumor-associated autoantibodies (AAbs). In this review, we summarize the latest progress of liquid biopsies, and their potential applications and challenges in the diagnosis of malignant pulmonary nodules.

Citing Articles

Development of a clinical prediction model for benign and malignant pulmonary nodules with a CTR ≥ 50% utilizing artificial intelligence-driven radiomics analysis.

Shi W, Hu Y, Chang G, Qian H, Yang Y, Song Y BMC Med Imaging. 2025; 25(1):21.

PMID: 39825237 PMC: 11742483. DOI: 10.1186/s12880-024-01533-9.

Knowledge mapping analysis of ground glass nodules: a bibliometric analysis from 2013 to 2023.

Wang L, Maolan A, Luo Y, Li Y, Liu R Front Oncol. 2024; 14:1469354.

PMID: 39381043 PMC: 11458373. DOI: 10.3389/fonc.2024.1469354.

Clinical value of peripheral blood miR-21 and miR-486 combined with CT forearly cancer diagnosis in pulmonary nodulessmoking.

Wang Z, Liu J, Liu Q, Ren Y, Wang Q, Tian Q J Cardiothorac Surg. 2024; 19(1):539.

PMID: 39304898 PMC: 11414282. DOI: 10.1186/s13019-024-03028-8.

Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG).

Jin Y, Mu W, Shi Y, Qi Q, Wang W, He Y EClinicalMedicine. 2024; 75:102769.

PMID: 39165498 PMC: 11334824. DOI: 10.1016/j.eclinm.2024.102769.

Signal-On Fluorescence Biosensor for Detection of miRNA-21 Based on ROX labeled Specific Stem-Loop Probe.

Heidarian S, Takbiri Osgoei L, Karizi S, Amani J, Arbabian S Iran J Pharm Res. 2024; 23(1):e144368.

PMID: 39005737 PMC: 11246647. DOI: 10.5812/ijpr-144368.

References

Xing L, Su J, Guarnera M, Zhang H, Cai L, Zhou R . Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res. 2015; 21(2):484-9. PMC: 4299920. DOI: 10.1158/1078-0432.CCR-14-1873. View

Mateo J, Gerlinger M, Nava Rodrigues D, de Bono J . The promise of circulating tumor cell analysis in cancer management. Genome Biol. 2014; 15(8):448. PMC: 4281949. DOI: 10.1186/s13059-014-0448-5. View

Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R . Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012; 157(11):776-84. DOI: 10.7326/0003-4819-157-11-201212040-00005. View

Han Y, Li H . miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC). J Thorac Dis. 2018; 10(5):3119-3131. PMC: 6006134. DOI: 10.21037/jtd.2018.05.32. View

Zheng J, Ye X, Liu Y, Zhao Y, He M, Xiao H . The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer. BMC Cancer. 2020; 20(1):106. PMC: 7011271. DOI: 10.1186/s12885-020-6524-1. View

Edelsberg J, Weycker D, Atwood M, Hamilton-Fairley G, Jett J . Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules. PLoS One. 2018; 13(5):e0197826. PMC: 5963796. DOI: 10.1371/journal.pone.0197826. View

Zeng H, He B, Yi C, Peng J . Liquid biopsies: DNA methylation analyses in circulating cell-free DNA. J Genet Genomics. 2018; 45(4):185-192. DOI: 10.1016/j.jgg.2018.02.007. View

Tao R, Cao W, Zhu F, Nie J, Wang H, Wang L . Liquid biopsies to distinguish malignant from benign pulmonary nodules. Thorac Cancer. 2021; 12(11):1647-1655. PMC: 8169297. DOI: 10.1111/1759-7714.13982. View

Massion P, Healey G, Peek L, Fredericks L, Sewell H, Murray A . Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol. 2016; 12(3):578-584. PMC: 5367043. DOI: 10.1016/j.jtho.2016.08.143. View

10.

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

11.

Mascalchi M, Maddau C, Sali L, Bertelli E, Salvianti F, Zuccherelli S . Circulating tumor cells and microemboli can differentiate malignant and benign pulmonary lesions. J Cancer. 2017; 8(12):2223-2230. PMC: 5560139. DOI: 10.7150/jca.18418. View

12.

Schmidt B, Weickmann S, Witt C, Fleischhacker M . Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci. 2008; 1137:207-13. DOI: 10.1196/annals.1448.034. View

13.

Bach P, Mirkin J, Oliver T, Azzoli C, Berry D, Brawley O . Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307(22):2418-29. PMC: 3709596. DOI: 10.1001/jama.2012.5521. View

14.

Buysschaert I, Schmidt T, Roncal C, Carmeliet P, Lambrechts D . Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med. 2009; 12(6B):2533-51. PMC: 3828872. DOI: 10.1111/j.1582-4934.2008.00515.x. View

15.

Xi K, Wang W, Wen Y, Chen Y, Zhang X, Wu Y . Combining Plasma miRNAs and Computed Tomography Features to Differentiate the Nature of Pulmonary Nodules. Front Oncol. 2019; 9:975. PMC: 6779729. DOI: 10.3389/fonc.2019.00975. View

16.

Jiang L, He C, Zhu Z . Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene. Oncotarget. 2017; 8(14):23675-23689. PMC: 5410336. DOI: 10.18632/oncotarget.15644. View

17.

Wang L, Chen Y, Tang K, Lin J, Zhang H . The Value of F-FDG PET/CT Mathematical Prediction Model in Diagnosis of Solitary Pulmonary Nodules. Biomed Res Int. 2018; 2018:9453967. PMC: 5896270. DOI: 10.1155/2018/9453967. View

18.

Henschke C, Yankelevitz D, Mirtcheva R, McGuinness G, McCauley D, Miettinen O . CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol. 2002; 178(5):1053-7. DOI: 10.2214/ajr.178.5.1781053. View

19.

Shen J, Liu Z, Todd N, Zhang H, Liao J, Yu L . Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11:374. PMC: 3175224. DOI: 10.1186/1471-2407-11-374. View

20.

Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao J . Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019; 9(7):2056-2070. PMC: 6485294. DOI: 10.7150/thno.28119. View